Abstract
Using a novel orthotopic MBT-2 murine bladder tumor model, we evaluated the feasibility of intravesical gene therapy utilizing a cationic liposome, DMRIE/DOPE. Superficial bladder tumors were consistently established by intravesical instillation of 5 × 105MBT-2 cells in syngeneic C3H female mice. In situ gene transfer to bladder tumors was accomplished via intravesical instillation of plasmid DNA/DMRIE/DOPE lipoplex. β-Galactosidase (β-gal) gene expression was preferentially evident in bladder tumors and was present for at least 7 days after a single 30 min in situ transfection. Murine interleukin-2 (IL-2) gene was used for treatment of 3-day-old pre-established bladder tumors. Forty percent of animals treated with IL-2 gene were completely free of tumors by 60 days following the initial tumor implantation, while all control groups treated with β-gal gene died. Those animals initially cured of pre-established tumors were completely resistant to a subsequent tumor re-challenge and their splenocyte-derived cytotoxic T lymphocytes were shown to be specific to MBT-2 cells, indicating that immunological memory against MBT-2 tumors was elicited by the treatment. These results demonstrate the possibility of an effective clinical application of this in situ intravesical IL-2 gene delivery system to high-risk superficial bladder tumors, obviating a need for tumor procurement and ex vivo gene transfer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Connor J et al. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells J Exp Med 1993 177: 1127–1134
Porgador A et al. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells Int J Cancer 1993 53: 471–477
Golumbek PT et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4 Science 1991 254: 713–716
Brunda MJ et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors J Exp Med 1993 178: 1223–1230
Porgador A et al. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells J Immunol 1993 150: 1458–1470
Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 1993 90: 3539–3543
Morales A, Eidinger D, Bruce AW . Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors J Urol 1976 116: 180–183
Ratliff TL, Gillen D, Catalona WJ . Requirement of a thymus dependent immune response for BCG-mediated antitumor activity J Urol 1987 137: 155–158
Ratliff TL et al. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer J Urol 1993 150: 1018–1023
Saito S et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines Cancer Res 1994 54: 3516–3520
Larchian WA et al. Liposome mediated gene transfer in human bladder cancer cells J Urol 1997 157: (Suppl.4) 307 (Abstr. 1196)
Larchian WA et al. Effectiveness of combined interleukin-2 and B7 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer Clin Cancer Res (submitted)
Parker SE et al. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo Cancer Gene Ther 1996 3: 175–185
Saffran DC et al. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity Cancer Gene Ther 1998 5: 321–330
Lee SS et al. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors Cancer Res 1994 54: 3325–3328
Werthman PE et al. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer J Urol 1996 155: 753–756
Harimoto K et al. In vivo gene transfer methods in the bladder without viral vectors Br J Urol 1998 81: 870–874
Soloway MS, Murphy WM . Experimental chemotherapy of bladder cancer – systemic and intravesical Semin Oncol 1979 6: 166–183
Raghavan D et al. Biology and management of bladder cancer New Engl J Med 1990 322: 1129–1138
Fidler IJ . Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes memorial award lecture Cancer Res 1990 50: 6130–6138
Shapiro A et al. Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin Cancer Res 1984 44: 3051–3054
Nativ O et al. Treatment of experimental mouse bladder tumour by LPS-induced epithelial cell shedding Br J Cancer 1996 74: 603–605
Van Pel A, Boon T . Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis Proc Natl Acad Sci USA 1982 79: 4718–4722
Huang AY et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens Science 1994 264: 961–965
Fearon ER et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response Cell 1990 60: 397–403
Jaffee EM et al. High efficiency gene transfer into primary human tumor explants without cell selection Cancer Res 1993 53: 2221–2226
Miller DG, Adam MA, Miller AD . Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection Mol Cell Biol 1990 10: 4239–4242
Felgner PL . Improvements in cationic liposomes for in vivo gene transfer Hum Gene Ther 1996 7: 1791–1793
Leimig T et al. High-efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin-2 vectors Hum Gene Ther 1996 7: 1233–1239
O'Malley BW Jr et al. Limitations of adenovirus-mediated interleukin-2 gene therapy for oral cancer Laryngoscope 1999 109: 389–395
Bass C et al. Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo Cancer Gene Ther 1995 2: 97–104
Felgner PL et al. Improved cationic lipid formulations for in vivo gene therapy Ann NY Acad Sci 1995 772: 126–139
Caplen NJ et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis Nature Med 1995 1: 39–46
Nabel GJ et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes Proc Natl Acad Sci USA 1996 93: 15388–15393
Stephan DJ et al. A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo Hum Gene Ther 1996 7: 1803–1812
Lee ER et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung Hum Gene Ther 1996 7: 1701–1717
Engler H et al. Ethanol improves adenovirus-mediated gene transfer and expression to the bladder epithelium of rodents Urology 1999 53: 1049–1053
Engler H et al. Enhanced adenovirus-mediated gene transfer to the urothelium for gene therapy of transitional cell carcinoma J Urol 1999 161: (Suppl.4) 120 (Abstr. 456)
Austin JC et al. Effects of volume and pressure during intravesical instillation of ALVAC-luciferase on levels of gene expression and systemic distribution J Urol 1999 161: (Suppl.4) 122 (Abstr. 462)
Egilmez NK et al. In vivo cytokine gene therapy of human tumor xenografts in SCID mice by liposome-mediated DNA delivery Gene Therapy 1996 3: 607–614
Hartikka J et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle Hum Gene Ther 1996 7: 1205–1217
Acknowledgements
We thank Robert Huryk for providing excellent technical assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Horiguchi, Y., Larchian, W., Kaplinsky, R. et al. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther 7, 844–851 (2000). https://doi.org/10.1038/sj.gt.3301157
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301157
Keywords
This article is cited by
-
Increased endocytosis of magnetic nanoparticles into cancerous urothelial cells versus normal urothelial cells
Histochemistry and Cell Biology (2018)
-
Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer
Molecular Cancer (2011)
-
Intravesical Treatments of Bladder Cancer: Review
Pharmaceutical Research (2008)
-
Immune gene therapy in urology
Current Urology Reports (2002)